Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

  • End date
    Dec 26, 2022
  • participants needed
  • sponsor
    National Cancer Institute (NCI)
Updated on 17 June 2022
major surgery
neutrophil count
liver metastasis
advanced cancer


  • Researchers want to find better ways to treat cancer. One drug that treats cancer is paclitaxel. Sometimes proteins block that drug from working. Researchers want to see if another drug, nilotinib, helps paclitaxel work better.
  • To test the safety of nilotinib plus paclitaxel and find out what doses of the drugs can be given safely to people.
  • Adults at least 18 years old with advanced cancer that has progressed after receiving standard treatment, or for which no effective therapy exists.
  • Participants will be screened with tests they usually get in their cancer care: medical history, physical exam, blood and urine tests, heart test, and scans.
  • Participants will take the two study drugs in 28-day cycles. They will keep a medicine diary.
  • Nilotinib will be taken by mouth twice every day except day 1 of the first cycle.
  • Paclitaxel will be given by IV once a week for the first 3 weeks of a cycle. This will usually be done at the clinic.
  • Most participants will have a weekly study visit every week for cycle 1, then the first 3 weeks of other cycles. They will have:
  • Physical exam at every visit.
  • Blood tests multiple times for cycle 1, then the first 3 weeks of other cycles.
  • Scans every 8 weeks. These may be CT or MRI scans, in a machine that takes pictures. Or they may be ultrasounds, where a wand is pressed on the skin with gel on it.
  • Around 30 days after stopping the study drugs, participants will be called to discuss any side effects.



-The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity

  • To establish the safety, tolerability, and maximum tolerated dose (MTD) of nilotinib plus paclitaxel in patients with refractory solid tumors, both in adult subjects >=18 years of age and in pediatric/adolescent subjects 12-17 years of age
  • To determine the pharmacokinetics of paclitaxel when administered in combination with nilotinib
  • To evaluate the pharmacodynamic effects of the combination on biomarkers of apoptosis, DNA damage response, and epithelial-to-mesenchymal transition
  • Study participants must have histologically confirmed solid tumor that has progressed on standard therapy known to prolong survival or for which no standard treatment options exist
  • Age greater than or equal to 12
  • No major surgery, radiation, or chemotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas and mitomycin C).
  • Adequate organ function

Study Design:

  • This is an open-label Phase I trial
  • During dose escalation, the starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
  • Up to 33 adult patients will be accrued to a PD expansion phase at the MTD to further assess pharmacodynamic endpoints in tumor and CTCs.
  • As of Amendment O (May 2020), patients ages 12-17 will be accrued to a separate pediatric expansion cohort to evaluate the safety, pharmacokinetics, and pharmacodynamics of this combination for pediatric patients.

Condition Solid Tumors
Treatment Nilotinib + Paclitaxel
Clinical Study IdentifierNCT02379416
SponsorNational Cancer Institute (NCI)
Last Modified on17 June 2022


Yes No Not Sure

Inclusion Criteria

Patients must have histologically confirmed solid tumors that have progressed on standard therapy known to prolong survival or for which no standard treatment options exist
Age greater than or equal to 12 years
ECOG performance status less than or equal to 2
Life expectancy of greater than 3 months
Patients must have normal organ and marrow function as defined below
Absolute neutrophil count greater than or equal to 1,500/mcL
Platelets greater than or equal to 100,000/mcL
Total bilirubin less than or equal to 1.5 X institutional ULN (with the exception of those with Gilbert syndrome, who must have total bilirubin <=3 X institutional ULN)
AST(SGOT)/ALT(SGPT) less than or equal to 3 X institutional upper limit of normal; 5.0 x ULN in patients with liver metastases
creatinine less than or equal to 1.5 X institutional ULN OR
creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels greater than 1.5 mg/dL
Nilotinib and paclitaxel have both been assigned to pregnancy category D by the FDA
Patients must have completed radiation therapy, or major surgery greater than or equal to 3 weeks, or biologic therapy or chemotherapy greater than or equal to 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosoureas and mitomycin C) prior to entering the study. Patients must be greater than or equal to 2 weeks since any prior administration of a study drug in a Phase 0 or equivalent study and be greater than or equal to1 week from palliative radiation therapy. Patients must have recovered to eligibility levels from prior toxicity or adverse events. Treatment with bisphosphonates is permitted
For this reason, women of child-bearing potential and men must agree to use
For the PD-expansion cohort, patients must be willing to give biopsies for research and have tumors amenable for the acceptable biopsy procedures- or in lieu of baseline biopsies, patient must have and be willing to submit at registration archival tumor biopsy tissue from a previous research study or medical care. Criteria for the submission of archival tissue are
adequate contraception (hormonal or barrier method of birth control
Tissue must have been collected within 3 months prior to registration
abstinence) prior to study entry and for the duration of study participation
Patient must not have received any intervening therapy for their cancer since the collection of the tumor sample
and for at least 3 months after dosing with study drugs ceases. Should a woman
Tumor tissue must meet the minimum requirements
become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician
immediately. Men treated or enrolled on this protocol must also agree to use
adequate contraception prior to the study, for the duration of study
participation, and 3 months after completion of study drug administration

Exclusion Criteria

QTcF interval of less than 450 msec at study entry; congenital long QT syndrome
Sensory/motor neuropathy less than or equal to Grade 2
Patients who are receiving any other investigational agents
Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial. Patients with treated brain metastases, whose brain metastatic disease has remained stable for less than or equal to 4 weeks without requiring steroid and anti-seizure medication are eligible to participate
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
Uncontrolled intercurrent illness including, but not limited to, serious untreated infection, symptomatic respiratory failure/congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study because nilotinib and paclitaxel have been assigned to pregnancy category D by the FDA. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
HIV-positive patients on combination antiretroviral therapy are ineligible because of possible PK interactions with study drugs
Both men and women of all races and ethnic groups are eligible for this trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note